Published on 21/12/2025
Using PSURs for Benefit-Risk Evaluation in Pharmacovigilance
Periodic Safety Update Reports (PSURs) are critical tools for assessing the benefit-risk balance of a pharmaceutical product during its post-marketing lifecycle. They serve not only to report cumulative safety data but also to contextualize these findings against the known benefits of the drug. A well-prepared PSUR enables sponsors and regulators to make informed decisions about product labeling, continued marketing, or necessary risk mitigation strategies. This guide explains how to effectively use PSURs for benefit-risk evaluation in compliance with global regulatory expectations.
What is Benefit-Risk Evaluation?
Benefit-risk evaluation is a core function of pharmacovigilance that compares the therapeutic benefits of a drug to its associated risks. These assessments are dynamic and evolve over time with new clinical data, adverse event reports, and real-world usage.
As per the EMA, the benefit-risk assessment is central to determining whether a drug’s market authorization should be maintained, modified, or withdrawn. PSURs are the structured vehicles through which this assessment is regularly updated and communicated.
How PSURs Enable Benefit-Risk Assessments
The PSUR provides a systematic framework to integrate:
- New and cumulative adverse event data
- Post-marketing clinical studies
- Updated exposure estimates
- Labeling changes and regulatory decisions
- Comparative safety data vs
Through this integration, sponsors and regulators can objectively reassess the balance between the benefits and risks of a product.
Relevant Sections of PSUR for Benefit-Risk Evaluation
- Section 6: Summary of Safety Concerns
- Section 7: Signal Evaluation
- Section 8: Integrated Benefit-Risk Analysis
- Section 9: Conclusions and Actions
These sections must align in content and tone. For example, new signals in Section 7 should be reflected in the updated benefit-risk analysis in Section 8, along with justifications for any proposed changes to the risk management plan (RMP).
Quantitative and Qualitative Approaches
Benefit-risk evaluations can be presented in two main formats:
1. Qualitative Assessment
- Uses expert medical judgment
- Describes how reported risks affect the overall safety profile
- Justifies whether the risk alters the favorable benefit-risk balance
2. Quantitative Models
- Applies statistical models such as Number Needed to Treat (NNT) and Number Needed to Harm (NNH)
- Used for chronic or high-risk products where risk is harder to interpret qualitatively
- Visual tools like benefit-risk grids, value trees, and forest plots
These tools can be implemented using software approved under validation master plans to ensure audit-ready outputs.
Incorporating Real-World Data in Benefit-Risk Analysis
PSURs should not rely solely on clinical trial results. They must integrate real-world data (RWD), including:
- Spontaneous AE reporting
- Product usage trends
- Off-label usage reports
- Stability testing results indicating quality-linked safety issues
- Patient feedback and compliance patterns
This multi-dimensional approach offers a richer, more realistic picture of benefit-risk balance.
Case Example: Benefit-Risk Reevaluation in Antidiabetics
Imagine a company marketing a novel antidiabetic agent detects an increased frequency of pancreatitis reports. In the latest PSUR:
- The company identifies the signal under Section 7
- Reviews severity, causality, and reversibility of the AE
- Compares data with similar agents on the market
- Updates Section 8 to reflect a slight reduction in the benefit-risk balance
- Proposes a label update and monitoring guideline in Section 9
Such integration demonstrates proactive pharmacovigilance and aligns with GMP compliance.
Best Practices for Benefit-Risk Evaluation in PSURs
- Ensure consistency between safety signal evaluations and benefit-risk narrative
- Use tabular presentations to summarize key risks and corresponding benefits
- Highlight any changes from the previous PSUR cycle
- Justify retention or modification of labeling, RMP, or product status
- Document internal benefit-risk decisions using SOP-compliant formats
Common Pitfalls to Avoid
- Over-reliance on clinical trial data and neglecting real-world signals
- Failure to address newly emerging risks in context of benefits
- Inconsistencies between different PSUR sections
- Unjustified conclusions lacking signal analysis depth
Regulatory Expectations
- EMA: Emphasizes integrated and transparent benefit-risk summaries
- USFDA: Expects direct linkage between signals and risk mitigation plans
- CDSCO: Requires benefit-risk narratives to justify product continuation
Failure to address benefit-risk thoroughly can delay PSUR acceptance or trigger additional post-marketing commitments.
Conclusion
Benefit-risk evaluation within a PSUR is not a checkbox task—it is a central pillar of ongoing pharmacovigilance. A structured, evidence-based benefit-risk section demonstrates a sponsor’s commitment to patient safety and regulatory transparency. By combining medical expertise with statistical tools, real-world data, and a consistent narrative, PSURs can effectively convey the evolving safety landscape of a product and support sound regulatory decision-making.